Table S1.
ESBL positivity and antibiotic susceptibility rates (%) for P. mirabilis and K. oxytoca isolates combined in HA vs CA IAIs and UTIs
| P. mirabilis ESBL +(n=28) | K. oxytoca ESBL +(n=23) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IAI | UTI | IAI | UTI | |||||||||
| All (n=13) | HA (n=13) | CA (n=0) | All (n=15) | HA (n=10) | CA (n=5) | ALL (n=8) | HA (n=7) | CA (n=1) | All (n=4) | HA (n=4) | CA (n=0) | |
| IPM | 7.69 | 7.69 | NA | 33.33 | 50 | 0 | 75 | 71.43 | 100 | 100 | 100 | NA |
| ETP | 92.31 | 92.31 | NA | 80 | 80 | 80 | 62.5 | 57.14 | 100 | 100 | 100 | NA |
| AMK | 92.31 | 92.31 | NA | 100 | 100 | 100 | 87.5 | 85.71 | 100 | 100 | 100 | NA |
| TZP | 84.62 | 84.62 | NA | 86.67 | 90 | 80 | 62.5 | 57.14 | 100 | 50 | 50 | NA |
| FOX | 92.31 | 92.31 | NA | 66.67 | 70 | 60 | 37.5 | 42.86 | 0 | 100 | 100 | NA |
| CAZ | 92.31 | 92.31 | NA | 80 | 80 | 80 | 12.5 | 14.29 | 0 | 25 | 25 | NA |
| CRO | 0 | 0 | NA | 6.67 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | NA |
| CTX | 0 | 0 | NA | 6.67 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | NA |
| FEP | 15.38 | 15.38 | NA | 6.67 | 10 | 0 | 12.5 | 0 | 100 | 0 | 0 | NA |
| LVX | 23.08 | 23.08 | NA | 33.33 | 50 | 0 | 50 | 57.14 | 0 | 25 | 25 | NA |
| CIP | 15.38 | 15.38 | NA | 13.33 | 20 | 0 | 50 | 57.14 | 0 | 25 | 25 | NA |
Abbreviations: HA, hospital-acquired; CA, community-acquired; IAI, intraabdominalinfection; UTI, urinary tract infection; IPM, Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam; FOX, Cephalosporins: Cefoxitin; CAZ, Ceftazidime; CRO, Ceftriaxone; CTX, Cefotaxime; FEP, Cefepime; LVX, Fluoroquinolones: Levofloxacin; CIP, Ciprofloxacin; NA, not available.